Recursion, Mila partner on tech-enabled drug discovery

By The Science Advisory Board staff writers

June 23, 2021 -- Digital biology company Recursion signed a multiyear deal with artificial intelligence (AI) research institute Mila to develop technology-enabled drug discovery.

Recursion leverages machine learning to unravel complex patterns of biology within biological datasets of more than 8 PB.

Under the deal, Recursion will open office space within Mila and build a team to improve its machine-learning capabilities. Mila's AI technology and experts will help Recursion improve the lives of patients while industrializing drug discovery.

Financial details of the collaboration were not disclosed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.